PM

Paul Manning

North America, Virginia, United States, Charlottesville

Description

Paul B. Manning has served as the chairman of our board of directors since December 2017 and as a member of our board of directors since Dec...

Investor Profile

Paul Manning has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series A (33%)
  • Post Ipo Equity (33%)
  • Grant (33%)

Country Focus

  • United States (67%)

Industry Focus

  • Health Care
  • Biotechnology
  • Nanotechnology
  • Therapeutics
  • Life Science
  • Biopharma
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Paul Manning frequently co-invest with?

Amplo
North America, Texas, United States, Spring
Co-Investments: 1
Narya Capital
North America, Ohio, United States, Columbus
Co-Investments: 1
CP
North America, New York, United States, New York
Co-Investments: 1
Bluebird Ventures
North America, California, United States, Palo Alto
Co-Investments: 1
JDRF T1D Fund
North America, Massachusetts, United States, Boston
Co-Investments: 1
Sahsen Ventures
North America, Washington, United States, Seattle
Co-Investments: 1
Foresite Capital
North America, California, United States, San Francisco
Co-Investments: 1
TC
North America, Michigan, United States, Ann Arbor
Co-Investments: 1
QVT Financial
North America, New York, United States, New York
Co-Investments: 1
Dexcel Pharma
Asia, Yerushalayim, Israel, Jerusalem
Co-Investments: 1

Which angels does Paul Manning often collaborate with?

Shared Deals: 1
RJ
North America, North Carolina, United States, Chapel Hill
Shared Deals: 1

What are some of recent deals done by Paul Manning?

The Paul and Diane Manning Institute of Biotechnology engages in the medical research that leads to new medical treatments.

Health CareMedicalNanotechnologyTherapeutics
GrantJan 20, 2023
Amount Raised: $300,000,000
Liquidia Technologies

Morrisville, North Carolina, United States

Liquidia Technologies is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics.

BiopharmaBiotechnologyHealth CareNanotechnologyTherapeutics
Post Ipo EquityApr 13, 2021
Amount Raised: $21,700,000
Kriya Therapeutics

Palo Alto, California, United States

Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.

BiotechnologyHealth CareLife Science
Series AMay 12, 2020
Amount Raised: $80,500,000